Genticel Société Anonyme, a clinical stage biotechnology company, develops immunotherapies to prevent cancers caused by the human papillomavirus (HPV). The company develops GTL001, a therapeutic vaccine that is in Phase II clinical trials in Europe, as well as in Phase I clinical trials in the United States for women infected with HPV 16 and/or HPV 18 before the appearance of cervical lesions or cancer. It also develops GTL002, a multivalent immunotherapy, which is in preclinical development that targets various HPV types, including HPV 16 and 18. Genticel Société Anonyme was founded in 2001 and is headquartered in Labège, France.
Labège, FR
Size (employees)
34 (est)
Genticel was founded in 2001 and is headquartered in Labège, FR

Genticel Office Locations

Genticel has an office in Labège
Labège, FR (HQ)
516 Rue Pierre et Marie Curie
Show all (1)

Genticel Financials and Metrics

Genticel Financials


Market capitalization (01-Mar-2017)

33.5 m

Closing share price (01-Mar-2017)

Genticel's current market capitalization is €33.5 m.
Show all financial metrics

Genticel Market Value History

Genticel's Web-traffic and Trends

Genticel News and Updates

Anal Cancer Market Research Report by regional analysis with forecast upto 2027

Market Research Future published a half cooked research report on “Global Anal Cancer Market Research Report - Forecast to 2027” – Market Analysis, Scope, Stake, Progress, Trends and Forecast…

Genticel Company Life and Culture

You may also be interested in